Form 4: Labcorp Director Victor Bulto Carulla Receives RSU Grant

Labcorp Holdings Inc. Director Victor Bulto Carulla was granted 773 Restricted Stock Units, vesting in February 2027.

Summary

• Victor Bulto Carulla, a Director of Labcorp Holdings Inc. (LH), acquired 773 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was February 10, 2026.
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• These 773 RSUs vest fully on February 10, 2027.
• Following this transaction, Victor Bulto Carulla beneficially owns an aggregate of 909 Restricted Stock Units.
• The acquisition price for these RSUs was $0, which is typical for equity grants as part of compensation.
• Kathryn W. Kyle has been appointed as the attorney-in-fact for Victor Bulto Carulla for Section 16 filings, effective December 9, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While a routine compensation disclosure, the grant of equity to a director generally signals alignment of interests with shareholders and incentivizes long-term performance.

Positives

• The grant of 773 Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule provides an incentive for long-term commitment and performance from the director.

Future Outlook

The 773 Restricted Stock Units granted to Director Victor Bulto Carulla are scheduled to vest fully on February 10, 2027, indicating a future milestone for this portion of his compensation.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a common form of equity compensation for directors and executives in the healthcare and diagnostics industry, including companies like Quest Diagnostics (DGX) or DaVita Inc. (DVA). This practice aims to align the interests of company leadership with long-term shareholder value creation by tying a portion of their compensation directly to the company's stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across publicly traded companies, including peers in the healthcare services sector such as Quest Diagnostics and Eurofins Scientific.
• The vesting schedule, typically over one to three years, is also consistent with industry norms designed to promote long-term retention and performance alignment.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The issuance of RSUs, upon vesting, will result in a minor dilution of existing shares, but also aligns the director's financial interests with long-term shareholder value.
• Director (Victor Bulto Carulla): Receives equity compensation, incentivizing performance and long-term commitment to the company.

Next Steps

• The 773 Restricted Stock Units will vest fully on February 10, 2027, at which point they will convert into shares of Labcorp Holdings Inc. Common Stock.

Key Dates

Keywords

Labcorp Holdings Inc., LH, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, SEC Form 4